183 related articles for article (PubMed ID: 33534940)
1. Dynamics of pseudo-atrophy in RRMS reveals predominant gray matter compartmentalization.
De Stefano N; Giorgio A; Gentile G; Stromillo ML; Cortese R; Gasperini C; Visconti A; Sormani MP; Battaglini M
Ann Clin Transl Neurol; 2021 Mar; 8(3):623-630. PubMed ID: 33534940
[TBL] [Abstract][Full Text] [Related]
2. Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing-remitting multiple sclerosis: A retrospective analysis.
Fisher E; Nakamura K; Lee JC; You X; Sperling B; Rudick RA
Mult Scler; 2016 Apr; 22(5):668-76. PubMed ID: 26238463
[TBL] [Abstract][Full Text] [Related]
3. Reduction in grey matter atrophy in patients with relapsing multiple sclerosis following treatment with cladribine tablets.
Cortese R; Battaglini M; Sormani MP; Luchetti L; Gentile G; Inderyas M; Alexandri N; De Stefano N
Eur J Neurol; 2023 Jan; 30(1):179-186. PubMed ID: 36168741
[TBL] [Abstract][Full Text] [Related]
4. MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a.
Gasperini C; Paolillo A; Giugni E; Galgani S; Bagnato F; Mainero C; Onesti E; Bastianello S; Pozzilli C
Mult Scler; 2002 Apr; 8(2):119-23. PubMed ID: 11990868
[TBL] [Abstract][Full Text] [Related]
5. Natalizumab reduces loss of gray matter and thalamic volume in patients with relapsing-remitting multiple sclerosis: A post hoc analysis from the randomized, placebo-controlled AFFIRM trial.
Nakamura K; Sun Z; Hara-Cleaver C; Bodhinathan K; Avila RL
Mult Scler; 2024 May; 30(6):687-695. PubMed ID: 38469809
[TBL] [Abstract][Full Text] [Related]
6. Two-year regional grey and white matter volume changes with natalizumab and fingolimod.
Preziosa P; Rocca MA; Pagani E; Storelli L; Rodegher M; Moiola L; Filippi M
J Neurol Neurosurg Psychiatry; 2020 May; 91(5):493-502. PubMed ID: 32111638
[TBL] [Abstract][Full Text] [Related]
7. The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis.
Dupuy SL; Khalid F; Healy BC; Bakshi S; Neema M; Tauhid S; Bakshi R
BMC Med Imaging; 2016 Oct; 16(1):56. PubMed ID: 27716096
[TBL] [Abstract][Full Text] [Related]
8. Effect of immunomodulatory medication on regional gray matter loss in relapsing-remitting multiple sclerosis--a longitudinal MRI study.
Bendfeldt K; Egger H; Nichols TE; Loetscher P; Denier N; Kuster P; Traud S; Mueller-Lenke N; Naegelin Y; Gass A; Kappos L; Radue EW; Borgwardt SJ
Brain Res; 2010 Apr; 1325():174-82. PubMed ID: 20167205
[TBL] [Abstract][Full Text] [Related]
9. Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: a randomised, single-blind, phase II study.
Schwartzbach CJ; Grove RA; Brown R; Tompson D; Then Bergh F; Arnold DL
J Neurol; 2017 Feb; 264(2):304-315. PubMed ID: 27888416
[TBL] [Abstract][Full Text] [Related]
10. Clinical and MRI efficacy of sc IFN β-1a tiw in patients with relapsing MS appearing to transition to secondary progressive MS: post hoc analyses of PRISMS and SPECTRIMS.
Freedman MS; Brod S; Singer BA; Cohen BA; Hayward B; Dangond F; Coyle PK
J Neurol; 2020 Jan; 267(1):64-75. PubMed ID: 31559532
[TBL] [Abstract][Full Text] [Related]
11. Intramuscular interferon beta-1a is effective in Japanese patients with relapsing-remitting multiple sclerosis: a pre-treatment versus treatment comparison study of gadolinium-enhanced MRI brain lesions.
Saida T; Itoyama Y; Tashiro K; Kira J; Hao Q;
Mult Scler; 2012 Dec; 18(12):1782-90. PubMed ID: 22492130
[TBL] [Abstract][Full Text] [Related]
12. Fingolimod effect on gray matter, thalamus, and white matter in patients with multiple sclerosis.
Gaetano L; Häring DA; Radue EW; Mueller-Lenke N; Thakur A; Tomic D; Kappos L; Sprenger T
Neurology; 2018 Apr; 90(15):e1324-e1332. PubMed ID: 29540589
[TBL] [Abstract][Full Text] [Related]
13. A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients.
Zivadinov R; Uher T; Hagemeier J; Vaneckova M; Ramasamy DP; Tyblova M; Bergsland N; Seidl Z; Dwyer MG; Krasensky J; Havrdova E; Horakova D
Mult Scler; 2016 Nov; 22(13):1709-1718. PubMed ID: 26883943
[TBL] [Abstract][Full Text] [Related]
14. Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy.
Zivadinov R; Locatelli L; Cookfair D; Srinivasaraghavan B; Bertolotto A; Ukmar M; Bratina A; Maggiore C; Bosco A; Grop A; Catalan M; Zorzon M
Mult Scler; 2007 May; 13(4):490-501. PubMed ID: 17463072
[TBL] [Abstract][Full Text] [Related]
15. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.
Havrdova E; Zivadinov R; Krasensky J; Dwyer MG; Novakova I; Dolezal O; Ticha V; Dusek L; Houzvickova E; Cox JL; Bergsland N; Hussein S; Svobodnik A; Seidl Z; Vaneckova M; Horakova D
Mult Scler; 2009 Aug; 15(8):965-76. PubMed ID: 19465443
[TBL] [Abstract][Full Text] [Related]
16. A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis.
Yousuf F; Dupuy SL; Tauhid S; Chu R; Kim G; Tummala S; Khalid F; Weiner HL; Chitnis T; Healy BC; Bakshi R
J Neurol Sci; 2017 Dec; 383():221-229. PubMed ID: 29146095
[TBL] [Abstract][Full Text] [Related]
17. Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.
Arnold DL; Calabresi PA; Kieseier BC; Sheikh SI; Deykin A; Zhu Y; Liu S; You X; Sperling B; Hung S
BMC Neurol; 2014 Dec; 14():240. PubMed ID: 25551571
[TBL] [Abstract][Full Text] [Related]
18. Cognitive impairment and memory disorders in relapsing-remitting multiple sclerosis: the role of white matter, gray matter and hippocampus.
Sacco R; Bisecco A; Corbo D; Della Corte M; d'Ambrosio A; Docimo R; Gallo A; Esposito F; Esposito S; Cirillo M; Lavorgna L; Tedeschi G; Bonavita S
J Neurol; 2015 Jul; 262(7):1691-7. PubMed ID: 25957638
[TBL] [Abstract][Full Text] [Related]
19. Subcutaneous recombinant interferon-β-1a (Rebif®): a review of its use in the treatment of relapsing multiple sclerosis.
Sanford M; Lyseng-Williamson KA
Drugs; 2011 Oct; 71(14):1865-91. PubMed ID: 21942977
[TBL] [Abstract][Full Text] [Related]
20. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
Zivadinov R; Dwyer MG; Hussein S; Carl E; Kennedy C; Andrews M; Hojnacki D; Heininen-Brown M; Willis L; Cherneva M; Bergsland N; Weinstock-Guttman B
Mult Scler; 2012 Aug; 18(8):1125-34. PubMed ID: 22194217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]